ATE261304T1 - Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne - Google Patents

Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne

Info

Publication number
ATE261304T1
ATE261304T1 AT99922459T AT99922459T ATE261304T1 AT E261304 T1 ATE261304 T1 AT E261304T1 AT 99922459 T AT99922459 T AT 99922459T AT 99922459 T AT99922459 T AT 99922459T AT E261304 T1 ATE261304 T1 AT E261304T1
Authority
AT
Austria
Prior art keywords
eletriptan
prevent migraine
migraine recurrence
recurrence
prevent
Prior art date
Application number
AT99922459T
Other languages
English (en)
Inventor
Neville Colin Jackson
Stephen Uden
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE261304T1 publication Critical patent/ATE261304T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99922459T 1998-07-30 1999-06-14 Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne ATE261304T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9816556.6A GB9816556D0 (en) 1998-07-30 1998-07-30 Therapy
PCT/IB1999/001105 WO2000006161A1 (en) 1998-07-30 1999-06-14 Prevention of migraine recurrence

Publications (1)

Publication Number Publication Date
ATE261304T1 true ATE261304T1 (de) 2004-03-15

Family

ID=10836395

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922459T ATE261304T1 (de) 1998-07-30 1999-06-14 Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne

Country Status (36)

Country Link
EP (3) EP1466601A3 (de)
JP (1) JP3824863B2 (de)
KR (2) KR20030078876A (de)
CN (2) CN1522697A (de)
AP (1) AP1402A (de)
AT (1) ATE261304T1 (de)
AU (1) AU3952199A (de)
BG (1) BG65309B1 (de)
BR (1) BR9912588A (de)
CA (1) CA2338901C (de)
CZ (1) CZ2001357A3 (de)
DE (1) DE69915486T2 (de)
DK (1) DK1100499T3 (de)
EA (2) EA200201149A1 (de)
EE (1) EE04703B1 (de)
ES (1) ES2214027T3 (de)
GB (1) GB9816556D0 (de)
GE (2) GEP20063719B (de)
HK (1) HK1038198A1 (de)
HR (1) HRP20010079A2 (de)
HU (1) HUP0103424A3 (de)
ID (1) ID26996A (de)
IL (1) IL140169A0 (de)
IS (1) IS2253B (de)
NO (1) NO20010489L (de)
NZ (2) NZ508736A (de)
OA (1) OA11576A (de)
PL (1) PL194611B1 (de)
PT (1) PT1100499E (de)
SG (1) SG125910A1 (de)
SK (1) SK1182001A3 (de)
TR (1) TR200100314T2 (de)
TW (2) TW537893B (de)
UA (1) UA76399C2 (de)
WO (1) WO2000006161A1 (de)
YU (2) YU6401A (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
MXPA05006954A (es) 2002-12-26 2005-09-22 Pozen Inc Formas de dosificacion de capas multiples que contienen nsaids y triptanos.
CA2521902A1 (en) 2003-04-11 2004-10-21 Pfizer Inc. Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
EP2306998A4 (de) 2008-06-20 2011-06-15 Alphapharm Pty Ltd Pharmazeutische formulierung
WO2011048496A1 (en) * 2009-10-23 2011-04-28 Fortuderm, Ltd. Triptans for the treatment of psoriasis
NO2838517T3 (de) 2012-04-18 2018-03-17
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法
CN104523709A (zh) * 2014-12-22 2015-04-22 青岛正大海尔制药有限公司 一种含有琥珀酸夫罗曲坦的复方缓释制剂
WO2018011181A1 (en) 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
EP0546593B1 (de) * 1991-10-30 1997-09-03 Glaxo Group Limited Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
JP2000505090A (ja) * 1996-07-11 2000-04-25 ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ インドール選択的セロトニンアゴニストを含む包接錯体
JP3350061B2 (ja) * 1997-07-03 2002-11-25 ファイザー・インク エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape

Also Published As

Publication number Publication date
EA004036B1 (ru) 2003-12-25
DE69915486T2 (de) 2005-03-03
NZ508736A (en) 2003-09-26
IL140169A0 (en) 2002-02-10
CA2338901C (en) 2008-02-19
JP3824863B2 (ja) 2006-09-20
AP2001002056A0 (en) 2001-03-31
EA200201149A1 (ru) 2003-02-27
BG65309B1 (bg) 2008-01-31
EP1100499A1 (de) 2001-05-23
NO20010489L (no) 2001-03-26
BG105277A (en) 2001-11-30
CN1155379C (zh) 2004-06-30
CA2338901A1 (en) 2000-02-10
AP1402A (en) 2005-04-29
EE200100061A (et) 2002-06-17
YU20303A (sh) 2006-08-17
PT1100499E (pt) 2004-06-30
HK1038198A1 (en) 2002-03-08
CN1522697A (zh) 2004-08-25
OA11576A (en) 2004-07-01
TR200100314T2 (tr) 2001-06-21
GEP20063719B (en) 2006-01-10
EP1435237A1 (de) 2004-07-07
NZ527625A (en) 2005-01-28
ES2214027T3 (es) 2004-09-01
TW200300674A (en) 2003-06-16
NO20010489D0 (no) 2001-01-29
EE04703B1 (et) 2006-10-16
EP1466601A2 (de) 2004-10-13
SG125910A1 (en) 2006-10-30
CN1309560A (zh) 2001-08-22
IS2253B (is) 2007-06-15
DE69915486D1 (de) 2004-04-15
EP1466601A3 (de) 2005-04-13
HUP0103424A3 (en) 2003-05-28
EA200100089A1 (ru) 2001-08-27
PL345803A1 (en) 2002-01-02
EP1100499B1 (de) 2004-03-10
GEP20043157B (en) 2004-01-26
JP2002521446A (ja) 2002-07-16
KR20030078876A (ko) 2003-10-08
IS5771A (is) 2000-12-15
DK1100499T3 (da) 2004-06-14
YU6401A (sh) 2004-03-12
AU3952199A (en) 2000-02-21
TWI248362B (en) 2006-02-01
WO2000006161A1 (en) 2000-02-10
CZ2001357A3 (cs) 2001-10-17
SK1182001A3 (en) 2001-10-08
TW537893B (en) 2003-06-21
UA76399C2 (en) 2006-08-15
KR100441732B1 (ko) 2004-07-27
BR9912588A (pt) 2001-05-02
ID26996A (id) 2001-02-22
KR20010079582A (ko) 2001-08-22
PL194611B1 (pl) 2007-06-29
HUP0103424A2 (hu) 2002-02-28
HRP20010079A2 (en) 2002-02-28
GB9816556D0 (en) 1998-09-30

Similar Documents

Publication Publication Date Title
ATE330935T1 (de) Inhibitoren der alpha4 vermittelten zelladhäsion
DE69739892D1 (de) Verwendung von perlförmigen Nahrungsmittelzusätzen
ATE291897T1 (de) Verwendung von zusammensetzungen mit stabilisierten enzymen
EE200000706A (et) Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
DE60037213D1 (de) Verwendung von Reinigungsgas
ATE253073T1 (de) Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69813616D1 (de) Cyclohexencarboxylate als inhibitoren der neuraminidase
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60020100D1 (de) Dimerverbindungen und als inhibitoren der neuramidinase
ATE261304T1 (de) Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne
DE60110232D1 (de) Neue verwendung von lipase-inhibitoren
DE69838042D1 (de) Verwendung von Inhibitoren des Renin-Angiotensin Systems
ATE224889T1 (de) Substituierte bisindolylmaleimide zur inhibierung der zellproliferation
DE59902868D1 (de) Verwendung von ectoin oder ectoin-derivaten in formulierungen
DK0944616T3 (da) Bicykliske arylcarboxamider og deres terapeutiske anvendelse
DE69934305D1 (de) Verwendung von dexmedetomidine zur sedierung auf der intensivstation
ATE243693T1 (de) Substituierte bisindolylmaleimide zur inhibierung der zellproliferation
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
ATE326969T1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
ATE363288T1 (de) Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
DE69924488D1 (de) Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms
ATE270545T1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
ATE303153T1 (de) Ibandroinsäure zur förderung der osseointegration der endoprothesen
ATE236653T1 (de) Kombination in feste dosiermenge von angiotensin- converting-enzyme-hemmern mit calcium-kanal antagonisten zur behandlung von herz- kreislauferkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1100499

Country of ref document: EP

REN Ceased due to non-payment of the annual fee